Sang-Yeon Suh1, Hong-Yup Ahn2. 1. Department of Family Medicine, Dongguk University International Hospital, 814 Siksa-dong, Ilsan-dong-gu, Koyang-si, Gyeonggi-do, Republic of Korea. lisasuhmd@hotmail.com. 2. Department of Statistics, Dongguk University, Seoul, Republic of Korea.
Abstract
GOALS OF WORK: C-reactive protein (CRP) has been investigated as a predictor of life expectancy in terminal cancer in one previous study. However, the other variables such as patient's symptom or physical examination findings were not considered. The aim of this study is to prove serum CRP level as a predictor of survival time, considering patient's symptoms, physical examination findings, and various serological variables in terminally ill cancer patients with a prospective cohort design. PATIENTS AND METHODS: Forty-four terminally ill cancer patients were divided into two groups by serum CRP levels and followed up until death. We adjusted the influence of some clinical and laboratory variables on survival by use of Cox's proportional hazard model. Using the stepwise variable selection method, we found the final model. For 19 patients, CRP levels at 2 weeks and a week before death were compared by Wilcoxon signed ranks test. MAIN RESULTS: All 44 study subjects died during the study period, and the median survival time was 17 days. Survival time of the elevated CRP group (> or =2.2 mg/dl) was found to be significantly shorter than the lower CRP group in univariate analysis (hazard rate = 3.221, P = 0.001). In multivariate analysis, elevated CRP level (> or =2.2 mg/dl) was selected as one of the unfavorable indicators regarding survival. Dyspnea and hyperbilirubinemia were also found significant predictors of shorter life expectancy in the final model. Serum CRP levels were significantly increased between the first and the second week before death. CONCLUSIONS: Our results showed that serum CRP level can be a useful indicator predictive of survival time of terminally ill cancer patients.
GOALS OF WORK: C-reactive protein (CRP) has been investigated as a predictor of life expectancy in terminal cancer in one previous study. However, the other variables such as patient's symptom or physical examination findings were not considered. The aim of this study is to prove serum CRP level as a predictor of survival time, considering patient's symptoms, physical examination findings, and various serological variables in terminally ill cancer patients with a prospective cohort design. PATIENTS AND METHODS: Forty-four terminally ill cancer patients were divided into two groups by serum CRP levels and followed up until death. We adjusted the influence of some clinical and laboratory variables on survival by use of Cox's proportional hazard model. Using the stepwise variable selection method, we found the final model. For 19 patients, CRP levels at 2 weeks and a week before death were compared by Wilcoxon signed ranks test. MAIN RESULTS: All 44 study subjects died during the study period, and the median survival time was 17 days. Survival time of the elevated CRP group (> or =2.2 mg/dl) was found to be significantly shorter than the lower CRP group in univariate analysis (hazard rate = 3.221, P = 0.001). In multivariate analysis, elevated CRP level (> or =2.2 mg/dl) was selected as one of the unfavorable indicators regarding survival. Dyspnea and hyperbilirubinemia were also found significant predictors of shorter life expectancy in the final model. Serum CRP levels were significantly increased between the first and the second week before death. CONCLUSIONS: Our results showed that serum CRP level can be a useful indicator predictive of survival time of terminally ill cancer patients.
Authors: Frank Kroschinsky; Matthias Weise; Thomas Illmer; Mathias Haenel; Martin Bornhaeuser; Gert Hoeffken; Gerhard Ehninger; Ulrich Schuler Journal: Intensive Care Med Date: 2002-07-18 Impact factor: 17.440
Authors: William G Hawkins; Ronald P DeMatteo; William R Jarnagin; Leah Ben-Porat; Leslie H Blumgart; Yuman Fong Journal: Ann Surg Oncol Date: 2004-03 Impact factor: 5.344
Authors: G Kasymjanova; N MacDonald; J S Agulnik; V Cohen; C Pepe; H Kreisman; R Sharma; D Small Journal: Curr Oncol Date: 2010-08 Impact factor: 3.677
Authors: Marianne R F Bosscher; Esther Bastiaannet; Barbara L van Leeuwen; Harald J Hoekstra Journal: Ann Surg Oncol Date: 2015-11-09 Impact factor: 5.344